Cargando…

Lack of UGT polymorphism association with idasanutlin pharmacokinetics in solid tumor patients

PURPOSE: Idasanutlin is a selective small-molecule MDM2 antagonist. It activates the tumor suppressor TP53 and is in phase 3 clinical trial for acute myeloid leukemia. Nonclinical studies have shown that glucuronidation is the major metabolizing mechanism for idasanutlin and UGT1A3 is the major meta...

Descripción completa

Detalles Bibliográficos
Autores principales:	So, W. Venus, Ou Yang, Tai-Hsien, Yang, Xing, Zhi, Jianguo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373577/ https://www.ncbi.nlm.nih.gov/pubmed/30511219 http://dx.doi.org/10.1007/s00280-018-3741-2

Ejemplares similares

Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors
por: Aregbe, Abdulateef O., et al.
Publicado: (2012)

Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus
por: Naagaard, M. Daniel, et al.
Publicado: (2022)

Meta-Analysis Reveals a Lack of Association between UGT2B17 Deletion Polymorphism and Tumor Susceptibility
por: Deng, Xiaheng, et al.
Publicado: (2014)

Effects of ABCB1, UGT1A1, and UGT1A9 Genetic Polymorphisms on the Pharmacokinetics of Sitafloxacin Granules in Healthy Subjects
por: Sun, Lu‐Ning, et al.
Publicado: (2020)

Rationale for Considering Oral Idasanutlin as a Therapeutic Option for COVID-19 Patients
por: Zauli, Giorgio, et al.
Publicado: (2020)

Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors
por: Italiano, Antoine, et al.
Publicado: (2021)

Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells
por: Skalniak, Lukasz, et al.
Publicado: (2018)

Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial
por: Konopleva, Marina Y., et al.
Publicado: (2022)

Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia
por: Johansson, Kimberly B., et al.
Publicado: (2023)

Lack of Association between Interleukin 12 C(-1188)A Polymorphism and Irritable Bowel Syndrome
por: Barkhordari, Elham, et al.
Publicado: (2011)

Lack of evidence for intermolecular epistatic interactions between adiponectin and resistin gene polymorphisms in Malaysian male subjects
por: Lau, Cia-Hin, et al.
Publicado: (2012)

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial
por: Daver, Naval G., et al.
Publicado: (2023)

Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir
por: Patel, Parul, et al.
Publicado: (2020)

Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy
por: Liu, Xing-Han, et al.
Publicado: (2017)

Differences in UGT1A1, UGT1A7, and UGT1A9 Polymorphisms between Uzbek and Japanese Populations
por: Maeda, Hiromichi, et al.
Publicado: (2014)

Lack of Association between ESR1 and CYP1A1 Gene Polymorphisms and Susceptibility to Uterine Leiomyoma in Female Patients of Iranian Descent
por: Taghizade Mortezaee, Fatemeh, et al.
Publicado: (2014)

Impact of UGT1A9 Polymorphism on Mycophenolic Acid Pharmacokinetic Parameters in Stable Renal Transplant Patients
por: Mazidi, Talia, et al.
Publicado: (2013)

Pharmacogenetics of uridine diphosphate glucuronosyltransferase (UGT2B7) genetic polymorphism on valproic acid pharmacokinetics in epilepsy
por: Munisamy, Murali, et al.
Publicado: (2014)

Impact of polymorphisms in CYP and UGT enzymes and ABC and SLCO1B1 transporters on the pharmacokinetics and safety of desvenlafaxine
por: Calleja, Sofía, et al.
Publicado: (2023)

Association between Food/UGT2B7 Polymorphisms and Pharmacokinetics/Pharmacodynamics Properties of Indapamide in Healthy Humans
por: Abbas, Banaz, et al.
Publicado: (2023)

Lack of association of -607 C/A and -137 G/C polymorphisms in interleukin 18 gene with susceptibility to gout disease in Chinese Han male population
por: Li, Changgui, et al.
Publicado: (2011)

The endemic GII.4 norovirus‐like‐particle induced‐antibody lacks of cross‐reactivity against the epidemic GII.17 strain
por: Du, Jialiang, et al.
Publicado: (2020)

Lack of evidence for conserved parasegmental grooves in arthropods
por: Janssen, Ralf, et al.
Publicado: (2022)

The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study
por: Mascarenhas, John, et al.
Publicado: (2022)

Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor
por: Hoebers, F. J. P., et al.
Publicado: (2007)

Lack of complex I is associated with oncocytic thyroid tumours
por: Zimmermann, F A, et al.
Publicado: (2009)

Physiologically‐Based Pharmacokinetic Modeling of the Drug–Drug Interaction of the UGT Substrate Ertugliflozin Following Co‐Administration with the UGT Inhibitor Mefenamic Acid
por: Callegari, Ernesto, et al.
Publicado: (2020)

Effect of esomeprazole on the pharmacokinetics of carbamazepine
por: Medhi, Bikash, et al.
Publicado: (2011)

Modeling ex vivo tumor-infiltrating lymphocyte expansion from established solid malignancies
por: Knochelmann, Hannah M, et al.
Publicado: (2021)

The effect of UGTs polymorphism on the auto-induction phase II metabolism-mediated pharmacokinetics of dihydroartemisinin in healthy Chinese subjects after oral administration of a fixed combination of dihydroartemisinin-piperaquine
por: Zang, Meitong, et al.
Publicado: (2014)

Lack of evidence of paratuberculosis in wild canids from Southwestern Europe
por: Sobrino, Raquel, et al.
Publicado: (2011)

Association of UGT2B7 and UGT1A4 Polymorphisms with Serum Concentration of Antiepileptic Drugs in Children
por: Du, Zhongliang, et al.
Publicado: (2016)

MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)
por: Khurana, Arushi, et al.
Publicado: (2019)

Does Weight Impact Anidulafungin Pharmacokinetics?
por: Lempers, Vincent J., et al.
Publicado: (2016)

Novel CDKs inhibitors for the treatment of solid tumour by simultaneously regulating the cell cycle and transcription control
por: Wang, Xin, et al.
Publicado: (2020)

Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients
por: Areepium, N, et al.
Publicado: (2013)

Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure
por: Marshall, Jean‐Claude, et al.
Publicado: (2021)

Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models
por: Lehmann, Christian, et al.
Publicado: (2016)

Polymorphisms of UGT1A1(*)6, UGT1A1(*)27 & UGT1A1(*)28 in three major ethnic groups from Malaysia
por: Teh, L. K., et al.
Publicado: (2012)

Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles
por: Xue, Mei, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_odchasfrud2sadru75ehv8gs3f